NAIAP Program

Developing new molecules to eliminate persistent bacteria

Bacterial persisters are a “dormant” subpopulation of cells that are tolerant or unresponsive to antibiotic treatment which can lead to chronic recurrent infection.

This subpopulation of non-growing bacteria can remain in a state of low metabolism for weeks or months in persistently infected patients, only to later “awaken,” often in a more aggressive form.

High persisters of Pseudomonas aeruginosa for example are selected in patients with cystic fibrosis and some nosocomial diseases .

Plateform to screen against persistent bacteria

When a population is treated with an antibiotic, regular cells die, whereas persisters survive. In order to kill, antibiotics require active targets, which explains persisters tolerance. This phenomenon is different from resistance mechanisms that arises due to the overuse of antibiotics. Microbial persisters can cause recurrent or intractable infections, causing chronic infections carrying an increasing clinical burden.

Our drug candidate derived from an analysis by artificial intelligence of a new mechanism of action has shown unique biological activity, able to specifically eliminate persistent bacteria. We aim at curing patients suffering from chronic infections and that suffer from infectious relapses.

OL2001 is Olgram’s lead candidate that specifically targets persistent bacteria.


We create a company that will save the life of many patients while creating a virtuous industrial process.

Learn more


We will be present at the following events, do not hesitate to contact us if you wish to meet.

Learn more